Literature DB >> 1080490

Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

H A Cooper, F F Reisner, M Hall, R H Wagner.   

Abstract

When human, canine, or bovine factor VIII preparations are chromatographed on 4% agarose at ionic strength 0.2, the factor VIII activity elutes as a single peak in the void volume with slight tailing. Incubation of such preparations with dilute (0.01 U/ml) highly purified thrombin results in some activation of factor VIII. Chromatography of such incubation mixtures, under the same conditions as before, results in elution of two peaks of factor VIII activity one in the void volume and one much later with marked tailing. The void volume peak has most of the protein and some factor VIII activity. These void volume fractions also contain all the von Willebrand factor activity of thrombin-treated bovine preparations. Longer treatment with thrombin, or treatment with stronger thrombin, appears to shift much more of the procoagulant activity to the later eluting peak. Also, when the peak of factor VIII activity, found in the void volume after thrombin treatment, was again incubated with dilute thrombin, an increase in factor VIII activity occurred. Chromatography of this incubation mixture demonstrated only a small amount of activity in the void volume, while the bulk of the activity was present in the second peak. On the other hand, thrombin treatment of factor VIII activity from peak 2 caused a rapid decline of activity instead of a further increase. It is proposed that the residual factor VIII activity found in the void volume represents unreacted factor VIII, while the late eluting peak represents thrombin-activated material that is of smaller apparent size. The late eluting peak differs from the small active factor VIII fragment obtained by Ca2+ dissociation, as the latter can be activated by thrombin. A similar set of experiments was performed using ultracentifugation of bovine factor VIII preparations on sucrose density gradients. Results of these experiments agreed completely with those obtained with get chromatography. Preparations made from human hemophilic plasma, by the procudure employed in the purification of human factor VIII, were also incubated with thrombin and chromatographed. von Willebrand factor was again found only in the void volume fractions, but there was no factor VIII activity in any fractions eluted. In other control experiments, activated and unactivated factor VIII fractions did not clot fibrinogen and contained no assayable factor IX or X. The thrombin-modified factor VIII of small size was inactivated by both a naturally occurring human inhibitor to factor VIII and the gamma globulin fraction of a rabbit antisera produced against the calcium-dissociated small active factor VIII fragment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1080490      PMCID: PMC301924          DOI: 10.1172/JCI108146

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity.

Authors:  S I RAPAPORT; S SCHIFFMAN; M J PATCH; S B AMES
Journal:  Blood       Date:  1963-02       Impact factor: 22.113

2.  Some factors that influence utilization of antihemophilic activity during clotting.

Authors:  G D PENICK
Journal:  Proc Soc Exp Biol Med       Date:  1957-11

3.  A simple ultraviolet spectrophotometric method for the determination of protein.

Authors:  W J WADDELL
Journal:  J Lab Clin Med       Date:  1956-08

4.  The Function of Ac-Globulin in Blood Clotting.

Authors:  A G Ware; R C Murphy; W H Seegers
Journal:  Science       Date:  1947-12-19       Impact factor: 47.728

5.  The action of thrombin on blood clotting factor V: conversion of factor V to a prothrombin-binding protein.

Authors:  C T Esmon; W G Owen; D L Duiguid; C M Jackson
Journal:  Biochim Biophys Acta       Date:  1973-05-17

6.  Isolation and characterization of human Factor VIII (antihemophilic factor).

Authors:  M E Legaz; G Schmer; R B Counts; E W Davie
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

7.  Expression and linkage of genes for X-linked hemophilias A and B in the dog.

Authors:  K M Brinkhous; P D Davis; J B Graham; W J Dodds
Journal:  Blood       Date:  1973-04       Impact factor: 22.113

8.  Preparation of modified bovine factor VIII with enhanced biological activity using insoluble-trypsin columns.

Authors:  C N Vogel; H E Parfitt; H S Kingdon; R L Lundblad
Journal:  Thromb Diath Haemorrh       Date:  1973-11

9.  Kidney antihemophilic factor. Partial purification and some properties.

Authors:  E M Barrow; J B Graham
Journal:  Biochemistry       Date:  1968-11       Impact factor: 3.162

10.  The mandatory role of lipid in the interaction of factors 8 and 9.

Authors:  S Schiffman; S I Rapaport; M M Chong
Journal:  Proc Soc Exp Biol Med       Date:  1966-12
View more
  7 in total

1.  The effects of epinephrine infusion in patients with von Willebrand's disease.

Authors:  F R Rickles; L W Hoyer; M E Rick; D J Ahr
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

2.  The properties of immune complexes formed by human antibodies to factor VIII.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Human platelet membrane receptor for bovine von Willebrand factor (platelet aggregating factor): an integral membrane glycoprotein.

Authors:  H A Cooper; K J Clemetson; E F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes.

Authors:  B A Perret; M Furlan; E A Beck
Journal:  Agents Actions       Date:  1981-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.